PER-014-05已完成未知
Phase II study of BMS-354825 in patients with accelerated phase chronic myeloid leukemia who are resistant or intolerant to treatment with imatinib mesylate
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •1) Patients must provide written informed consent.
- •2) Subjects with accelerated phase chromic leukemia, which are Ph + chromosome (or BGR / ABL +), whose disease has primary or acquired haematological resistance to the imatinib mesylate. or are intolerant to Imatinib mesylate.
- •3) Available for scheduled follow-up
- •4) Score of 0 - 2 in the performance status ECOG
- •5) Adequate liver function.
- •6) Adequate renal function.
- •7) Serum levels of potassium and magnesium within normal limits.
- •8) Men and women 18 years of age or older
排除标准
- •1) MEF that are not willing or able to use a method of birth control.
- •2) MEF who are using a prohibited contraceptive method.
- •3) MEF who are pregnant or breast-feeding
- •4) Women who have obtained a positive result in the pregnancy test performed.
- •5) Sexually active men whose sexual partners may become pregnant, unwilling or unable to use a method of birth control that is acceptable
- •6) Subjects that are eligible and willing to undergo a transplant during the selection period
- •7) Severe uncontrolled medical condition or active infection that could impair the possibility of the subject receiving the protocol therapy;
- •8) Significant or uncontrolled cardiovascular disease
- •9) Dementia or mental state altered.
- •10) History of significant hemorrhagic disorder not associated with CML
- •11) Concurrent incurable neoplasia different from CML.
- •12) Evidence of organic dysfunction or dysfunction dlgestiva.
- •13) Subjects who received any of the following: a) Imatinib mesylate in the previous 7 days b) Interferon or cytarabine in the previous 14 days c) An antineoplastic molecule within the previous 14 days d) Any other antineoplastic or investigational drug within the previous 28 days.
- •14) Individuals currently taking: Quinidine, procainamide, disopyramide, Amiodarone, sotalol, ibutilide, dofetilide, erythromlcins, clarithromycin, chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, cizapride, bepridil, droperidol, methadone, arsenic, c-orochin , domperidone, halofantrine, levomethadyl, panetamidine, sparfloxacin, lidoflazine.
- •15) Individuals who are taking medications that
- •irreversibly inhibit platelet function.
- •16) Previous therapy with BMS-354825
- •17) Prisoners or patients, who have been detained, may not be enrolled in this study.
- •against your will
研究者
相似试验
进行中（未招募）
不适用
A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib MesylateEUCTR2004-002515-89-ITBRISTOL-M.SQUIBB256
进行中（未招募）
不适用
A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic MyeloidLeukemia Resistant to or Intolerant of Imatinib MesylateRevised Protocol 01: Incorporates Amendment 03 and Administrative Letter dated 01-March-2005.Amendment 01 country specific version 1.0 dated 2005-03-14Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib MesylateEUCTR2004-002515-89-BEBristol-Myers Squibb International Corporation256
进行中（未招募）
不适用
A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic MyeloidLeukemia Resistant to or Intolerant of Imatinib MesylateRevised Protocol 01: Incorporates Amendment 03 and Administrative Letter dated 01-March-2005.Amendment 01 country specific version 1.0 dated 2005-03-14EUCTR2004-002515-89-SEBristol Myers Squibb International Corporation256
进行中（未招募）
不适用
A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic MyeloidLeukemia Resistant to or Intolerant of Imatinib MesylateProtocol version 1.0 dated 2004-10-05, andAmendment 01 country specific version 1.0 dated 2005-03-14Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib MesylateEUCTR2004-002515-89-ATBristol Myers Squibb International Corporation256
进行中（未招募）
1 期
A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic MyeloidLeukemia Resistant to or Intolerant of Imatinib Mesylate.Revised Protocol 01: Incorporates Amendment 03 and Administrative Letter dated 01-March-2005.Amendment 01 country specific version 1.0 dated 2005-03-14Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib MesylateEUCTR2004-002515-89-GBBristol-Myers Squibb International Corporation256